Table 1 GATA3 expression and clinical characteristics of ccRCC

From: GATA3 suppresses human fibroblasts-induced metastasis of clear cell renal cell carcinoma via an anti-IL6/STAT3 mechanism

Variables

Number (total n = 534)

GATA3 expression

P-value

  

Low

High

 

Age (yr)

   

0.3867

 ≤60

264 (49.44%)

137

127

 

 >60

270 (50.56%)

130

140

 

Gender

   

0.1029

 Male

346 (64.79%)

164

182

 

 Female

188 (35.21%)

103

85

 

Tumor size

   

0.0122*

 T1

273 (51.12%)

153

120

 

 T2

69 (12.92%)

35

34

 

 T3

181 (33.90%)

76

105

 

 T4

11 (2.06%)

3

8

 

Lymph nodes metastasis

   

0.8696*

 N0

240 (44.94%)

117

123

 

 N1

16 (3.00%)

8

8

 

 N/A

278 (52.06%)

142

136

 

Distant metastasis

   

0.0112*

 M0

424 (79.40%)

212

212

 

 M1

80 (14.98%)

33

47

 

 N/A

30 (5.62%)

22

8

 

Stage

   

0.0204*

 I

269 (50.38%)

151

118

 

 II

57 (10.67%)

29

28

 

 III

123 (23.03%)

50

73

 

 IV

85 (15.92%)

37

48

 
  1. N/A not available
  2. All data of the 534 patients with ccRCC were collected from TCGA database. Low GATA3 expression: lower than the median level of GATA3 expression of total patients. High GATA3 expression: higher than the median level of GATA3 expression of total patients. The patients’ number in each district was counted and analyzed by chi-square test. The statistical results suggest that the expression of GATA3 was significantly correlated with the tumor size, distant metastasis, and pathologic stage. However, there is no significant association between GATA3 expression and patients’ age, gender, and lymph nodes metastasis
  3. *P < 0.05
Back to article page